title: Effect of cyclosporine on apoptosis in bronchial epithelial cells.
abstract: OBJECTIVE
  Among airway complications, posttransplantation infections are related to impaired mucociliary clearance, which may represent a toxicity of cyclosporine (CsA), a potent, widely used immunosuppressive drug after organ transplantations. Since several recent studies have demonstrated CsA treatment to directly induce apoptosis in several cell types, we investigated its effects on airway cells using the human bronchial epithelial cell line BEAS-2B.
  
  
  METHODS
  Proliferation was measured by using a Cell Counting Assay Kit by exposing cells to CsA (0, 10, 30, 50, or 100 μg/mL). Apoptotic cells were identified using fluorescence microscopy after 4', 6-diamidino-2-phenylidole (DAPI) staining. Western blot analysis was performed to evaluate the contents of poly(adenosine diphosphate-ribose) polymerase (PARP), p27, Bcl-2, and caspase-3.
  
  
  RESULTS
  Cell viability decreased dependent on the CsA concentration: 100.00 ± 0.01% with 0 μg CsA as control; 98.65 ± 0.02% with 10 μg (P < .05 vs control); 95.41 ± 0.05% with 30 μg (P < .05 vs control); 38.84 ± 0.04% (P < .001 vs control) with 50 μg; and 15.28 ± 0.05% with 100 μg (P < .001 vs control). Apoptotic cells detected with DAPI showed chromatin condensation and nuclear fragmentation. CsA induced p27 and p53, as well as degradation of 116-kd PARP into an 89-kd fragment.
  
  
  CONCLUSIONS
  CsA induced apoptosis in human bronchial epithelial cells.
authors.affiliation: Kidney Institute, Keimyung University, Daegu, Korea.
authors.forename: E Y
authors.initials: EY
authors.lastname: Ha
authors.forename: K C
authors.initials: KC
authors.lastname: Mun
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D001980:Bronchi / Q000187:drug effects* / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism; D016572:Cyclosporine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008856:Microscopy, Fluorescence; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: C436291:CDKN1B protein, human; D007166:Immunosuppressive Agents; D019253:Proto-Oncogene Proteins c-bcl-2; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D050760:Cyclin-Dependent Kinase Inhibitor p27; D016572:Cyclosporine; D011065:Poly(ADP-ribose) Polymerases; C505407:CASP3 protein, human; D053148:Caspase 3